Epilepsy Drug Treatment

LONDON— GW Pharmaceuticals PLC said its Epilepsy Drug Treatment marijuana-derived drug for children with severe epilepsy significantly cut the number of seizures they suffered during a Phase III trial, possibly paving the way for the first U.S. approval of a drug of its kind.Shares in the company more than doubled in trading Monday, rising 140% to close at 519 pence ($7.46) in London.

The drug, called Epidiolex Epilepsy Drug Treatment , reduced the frequency of seizures by 39% in children with a severe form of epilepsy known as Dravet syndrome, compared with a 13% reduction in a control group, over a treatment period of 14 weeks.GWPharma said it planned to use the data to file for approval of the drug with the U.S. Food and Drug Administration, which has already granted the drug certain priority designations to accelerate its approval.

Prev1 of 4
Continue Reading on Next Page

Leave A Reply

error: Content is protected !!